Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

Contributed by: Business Wire

Logo

Tags

Science

Neurology

Biotechnology

Research

Pharmaceutical

Optical

Health

Clinical Trials

Phase 3 Study of Cenegermin-bkbj

More Like This

Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy

Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis

Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10

Allogeneic Cell Therapy to Treat Corneal Endothelial Disease (Graphic: Business Wire)

Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain

Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference